60 Degrees Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: SXTPW · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $1, $0, $4 m, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
60 Degrees Pharma inked a material deal and sold equity on Sept 4th. Check the filings.
AI Summary
On September 4, 2024, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- 60 Degrees Pharmaceuticals, Inc. (company) — Registrant
- September 4, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did 60 Degrees Pharmaceuticals, Inc. enter into?
The filing states that 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement on September 4, 2024, but the specific details of the agreement are not provided in the excerpt.
What was the purpose of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities, but the purpose or details of these sales are not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 4, 2024.
What is the Commission File Number for 60 Degrees Pharmaceuticals, Inc.?
The Commission File Number for 60 Degrees Pharmaceuticals, Inc. is 001-41719.
What is the Standard Industrial Classification (SIC) code for 60 Degrees Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for 60 Degrees Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,757 words · 7 min read · ~6 pages · Grade level 12.3 · Accepted 2024-09-06 16:10:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
- $1 — a price per Pre-funded Warrant equal to $1.379, the per share Purchase Price (as d
- $0 — defined in the Purchase Agreement) less $0.001, the exercise price of the Pre-fund
- $4 m — s") for gross proceeds of approximately $4 million, before the deduction of placemen
- $0.001 — nded Warrants have an exercise price of $0.001 per share, will become exercisable upon
- $1.38 — mmon Warrants have an exercise price of $1.38 per share and will be exercisable begin
- $4.0 million — the Private Placement of approximately $4.0 million in gross proceeds, before deducting the
- $85,000 — also agreed to pay the Placement Agent $85,000 for non-accountable expenses. The Compa
- $1.725 — arrants have an exercise price equal to $1.725 per share and are exercisable beginning
Filing Documents
- ea0213757-8k_60degrees.htm (8-K) — 55KB
- ea021375701ex10-1_60degrees.htm (EX-10.1) — 249KB
- ea021375701ex10-2_60degrees.htm (EX-10.2) — 139KB
- ea021375701ex10-3_60degrees.htm (EX-10.3) — 91KB
- ea021375701ex10-4_60degrees.htm (EX-10.4) — 92KB
- ea021375701ex10-5_60degrees.htm (EX-10.5) — 92KB
- ea021375701ex10-6_60degrees.htm (EX-10.6) — 94KB
- ea021375701ex99-1_60degrees.htm (EX-99.1) — 11KB
- ea021375701ex99-2_60degrees.htm (EX-99.2) — 11KB
- 0001213900-24-076515.txt ( ) — 1258KB
- sxtp-20240904.xsd (EX-101.SCH) — 4KB
- sxtp-20240904_def.xml (EX-101.DEF) — 26KB
- sxtp-20240904_lab.xml (EX-101.LAB) — 36KB
- sxtp-20240904_pre.xml (EX-101.PRE) — 25KB
- ea0213757-8k_60degrees_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: September 6, 2024 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 4